Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)
Summary
This is a randomized, double-blind, placebo-controlled study. The hypothesis for this study is that single oral doses of MK-8266 selected for this study are sufficiently safe and well tolerated by elderly male and elderly female participants with hypertension to permit continued clinical investigation.
Timeline
- Start
- 2010-11-01
- Primary completion
- 2011-02-01
- Completion
- 2011-03-01
Outcome
Mixed primary results
registry Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN); p = 0.0416; Mean Difference (Final Values) -10.1 (90% CI -19.6 to -0.56); ANOVA NCT01263314 ↗
registry Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN); p = 0.3551; Mean Difference (Final Values) -1.25 (90% CI -7.01 to 4.50); ANOVA NCT01263314 ↗
registry Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN); p = 0.0434; Mean Difference (Final Values) 4.12 (90% CI 0.18 to 8.05); ANOVA NCT01263314 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-8266 | Unknown | 0.3 mg | Oral |
| Subject | MK-8266 | Unknown | 0.6 mg | Oral |
| Subject | MK-8266 | Unknown | 0.7 mg | Oral |